Non-AIDS-Defining Malignancies in the HIV-Infected Population
- 323 Downloads
With the advent of effective combination antiretroviral therapy, HIV infection has been transformed from a fatal disease to a chronic condition. There is renewed clinical interest in long-term morbidities, including malignancies that occur disproportionately within this population. Non-AIDS-defining cancers (NADCs) are a significant source of morbidity and mortality in the aging HIV-infected population. There are data to suggest that incidence rates are elevated among HIV-infected individuals for many cancer sites, particularly those with a confirmed or suspected infectious etiology. The complex interplay between behavioral risk factors, coexistence of viral infections, immunodeficiency and antiretroviral therapy makes it difficult to analyze why certain cancers develop more frequently in HIV-infected individuals. The challenge to clinicians caring for HIV-infected patients is to develop and implement effective means to screen, treat, and prevent NADCs in the future. This review presents data on whether NADCs are increased in the HIV-Infected population, as well as ongoing research on epidemiology, prevention and pathogenesis of this evolving aspect of the HIV epidemic.
KeywordsHIV/AIDS Cancer Epidemiology Lung cancer
Compliance with Ethics Guidelines
Conflict of Interest
Chia-Ching Wang received travel expense reimbursement from Prime Oncology. Michael Silverberg received grants from Merck and Pfizer. Donald Abrams declares no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Castro KG, Ward JW, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19.Google Scholar
- 15.••Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62. Used data from the HIV/AIDS Cancer Match Study, which links 15 US population-based HIV and cancer registries, and from the Centers for Disease Control and Prevention.PubMedCentralPubMedCrossRefGoogle Scholar
- 16.CDC. HIV surveillance report, 2011, vol. 23. Atlanta: Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed 28 March 2014.
- 19.Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49:1570–8.PubMedCentralPubMedCrossRefGoogle Scholar
- 31.US Census Bureau. Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2010. Washington, DC: US Census Bureau; 2010.Google Scholar
- 32.Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/. Accessed 28 March 2014.
- 39.•Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458–65. Patients starting combination antiretroviral therapy (cART) as of 1 January 1996 were selected from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. Cumulative exposure to CD4+ cell counts <200 cells/mm3 during cART was associated with an increased risk of infection-related non-AIDS-defining malignancies.PubMedCrossRefGoogle Scholar
- 40.•Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9. Compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.PubMedCentralPubMedCrossRefGoogle Scholar
- 41.Cogliano V, Bann R, Straif K, et al. WHO. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 90. Human papillomaviruses. Lyon: International Agency for Research on Cancer; 2007. p. 1–670.Google Scholar
- 61.•Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55:510–5. Prospective study of 2,495 HIV-infected and HIV-uninfected injection drug users in Baltimore with cancer data from Cancer Registry.PubMedCentralPubMedCrossRefGoogle Scholar
- 67.Mueller N. Hodgkin’s disease. In: Schottenfeld D, Fraumeni Jr JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 893–919.Google Scholar
- 72.Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2003;101:4283–97.Google Scholar
- 74.Rosenwald AG, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.PubMedCentralPubMedCrossRefGoogle Scholar
- 76.Muller N. Overview of the epidemiology of malignancy in immune deficiency. J Acquir Immune Defic Syndr. 1999;21:S5–10.Google Scholar